These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 34139729)

  • 1. [Efficacy of Tapentadol for Neuropathic Pain in Cancer].
    Takahara Y; Tanahashi J; Murota K; Imai M; Takagi Y; Kimata T
    Gan To Kagaku Ryoho; 2021 Jun; 48(6):811-814. PubMed ID: 34139729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of tapentadol for first-line opioid-resistant neuropathic pain in Japan.
    Sugiyama Y; Kataoka T; Tasaki Y; Kondo Y; Sato N; Naiki T; Sakamoto N; Akechi T; Kimura K
    Jpn J Clin Oncol; 2018 Apr; 48(4):362-366. PubMed ID: 29506199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tapentadol in pain management: a μ-opioid receptor agonist and noradrenaline reuptake inhibitor.
    Hartrick CT; Rozek RJ
    CNS Drugs; 2011 May; 25(5):359-70. PubMed ID: 21476608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain.
    Schröder W; Vry JD; Tzschentke TM; Jahnel U; Christoph T
    Eur J Pain; 2010 Sep; 14(8):814-21. PubMed ID: 20541444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tapentadol, but not morphine, selectively inhibits disease-related thermal hyperalgesia in a mouse model of diabetic neuropathic pain.
    Christoph T; De Vry J; Tzschentke TM
    Neurosci Lett; 2010 Feb; 470(2):91-4. PubMed ID: 20026182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tapentadol in Cancer Patients with Neuropathic Pain: A Comparison of Methadone, Oxycodone, Fentanyl, and Hydromorphone.
    Takemura M; Niki K; Okamoto Y; Matsuda Y; Omae T; Takagi T; Ueda M
    Biol Pharm Bull; 2021; 44(9):1286-1293. PubMed ID: 34471056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study.
    Baron R; Likar R; Martin-Mola E; Blanco FJ; Kennes L; Müller M; Falke D; Steigerwald I
    Pain Pract; 2016 Jun; 16(5):580-99. PubMed ID: 26095455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tapentadol is effective in the management of moderate-to-severe cancer-related pain in opioid-naïve and opioid-tolerant patients: a retrospective study.
    Sazuka S; Koitabashi T
    J Anesth; 2020 Dec; 34(6):834-840. PubMed ID: 32648017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology update: tapentadol for neuropathic pain.
    Pierce DM; Shipstone E
    Am J Hosp Palliat Care; 2012 Dec; 29(8):663-6. PubMed ID: 22310021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective, multicenter, open-label study of the clinical efficacy of tapentadol extended-release in the treatment of cancer-related pain and improvement in the quality of life of opioid-naïve or opioid-resistant patients.
    Jung JY; Chon HJ; Choi YJ; Yeon SE; Choi SY; Lee KH
    Support Care Cancer; 2022 Jul; 30(7):6103-6112. PubMed ID: 35420330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain.
    Sánchez Del Águila MJ; Schenk M; Kern KU; Drost T; Steigerwald I
    Clin Ther; 2015 Jan; 37(1):94-113. PubMed ID: 25108647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tapentadol: with two mechanisms of action in one molecule effective against nociceptive and neuropathic pain. Preclinical overview].
    Tzschentke TM; Christoph T; Schröder W; Englberger W; De Vry J; Jahnel U; Kögel BY
    Schmerz; 2011 Feb; 25(1):19-25. PubMed ID: 21258822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study.
    Steigerwald I; Müller M; Davies A; Samper D; Sabatowski R; Baron R; Rozenberg S; Szczepanska-Szerej A; Gatti A; Kress HG
    Curr Med Res Opin; 2012 Jun; 28(6):911-36. PubMed ID: 22443293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual μ-opioid receptor and norepinephrine reuptake mechanisms contribute to dezocine- and tapentadol-induced mechanical antiallodynia in cancer pain.
    Mao XF; Ahsan MZ; Apryani E; Tang XQ; Zhao MJ; Li XY; Wang YX
    Eur J Pharmacol; 2020 Jun; 876():173062. PubMed ID: 32173379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tapentadol in neuropathic pain cancer patients: a prospective open label study.
    Galiè E; Villani V; Terrenato I; Pace A
    Neurol Sci; 2017 Oct; 38(10):1747-1752. PubMed ID: 28699105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antinociceptive and antihyperalgesic effect of tapentadol is partially retained in OPRM1 (μ-opioid receptor) knockout mice.
    Kögel B; De Vry J; Tzschentke TM; Christoph T
    Neurosci Lett; 2011 Mar; 491(2):104-7. PubMed ID: 21232580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of tapentadol in pain management.
    Mendis V
    Br J Hosp Med (Lond); 2012 Mar; 73(3):143-7. PubMed ID: 22411644
    [No Abstract]   [Full Text] [Related]  

  • 18. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study.
    Gálvez R; Schäfer M; Hans G; Falke D; Steigerwald I
    Adv Ther; 2013 Mar; 30(3):229-59. PubMed ID: 23475406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-label, Phase 3b/4 Trial.
    Baron R; Jansen JP; Binder A; Pombo-Suarez M; Kennes L; Müller M; Falke D; Steigerwald I
    Pain Pract; 2016 Jun; 16(5):600-19. PubMed ID: 26554630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tapentadol: A Review of Experimental Pharmacology Studies, Clinical Trials, and Recent Findings.
    Alshehri FS
    Drug Des Devel Ther; 2023; 17():851-861. PubMed ID: 36974332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.